Capital Research Global Investors Buys 3,383,559 Shares of ADMA Biologics Inc $ADMA

Capital Research Global Investors lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 104.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,637,472 shares of the biotechnology company’s stock after acquiring an additional 3,383,559 shares during the quarter. Capital Research Global Investors’ holdings in ADMA Biologics were worth $121,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Rothschild Investment LLC raised its position in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,495 shares during the last quarter. Optima Capital LLC bought a new position in shares of ADMA Biologics during the fourth quarter worth about $36,000. Clearstead Advisors LLC raised its position in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 795 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics during the third quarter worth about $34,000. Finally, RiverPark Advisors LLC bought a new position in shares of ADMA Biologics during the third quarter worth about $35,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Up 1.1%

Shares of ADMA Biologics stock opened at $8.06 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $22.37. The stock has a 50 day moving average price of $9.24 and a two-hundred day moving average price of $14.37. The stock has a market capitalization of $1.87 billion, a PE ratio of 11.85 and a beta of 0.73.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. During the same quarter last year, the firm posted $0.11 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the purchase, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.90% of the company’s stock.

Wall Street Analyst Weigh In

ADMA has been the subject of several recent analyst reports. Zacks Research cut ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Canaccord Genuity Group decreased their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Mizuho decreased their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.